Dorothy Keefe
Adelaide Medical School
Faculty of Health and Medical Sciences
Professor Keefe is the CEO of Cancer Australia, and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist, and Professor of Cancer Medicine.Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer more broadly, Medical Leadership and Health Reform, and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients .
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Professor Keefe is the Interim Director of the SA Cancer Service, Professor of Cancer Medicine at the University of Adelaide, and a Senior Medical Oncologist at Royal Adelaide Hospital. She is a Past-President of the Multinational Association of Supportive Care in Cancer (MASCC).
Dorothy Keefe graduated in Medicine from the University of London in 1986, migrated to Australia and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 1996. She received her Doctorate of Medicine from the University of Adelaide in 1999, for a thesis entitled ‘The effect of cytotoxic chemotherapy on the mucosa of the small intestine’.
Professor Keefe’s research interest is in toxicity of cancer treatment, particularly mucositis and how it links to other toxicities. Her laboratory work investigates chemotherapy and radiotherapy-induced whole gut damage, and the efficacy of new agents in prevention and treatment. She has authored over 100 peer-reviewed publications in this area.
In the 2013 Queen’s Birthday Honours Professor Keefe received the Public Service Medal for “outstanding service in the areas of Public Health, Medical Research and Oncology”. And in 2014 she received the MASCC Distinguished Service Award for “longstanding, devoted and exemplary service to MASCC”.
She has recently completed a Master’s of Science (MSc) in Medical Leadership at Birbeck College, University of London and her thesis was titled “Using Clinical Leadership to Drive Success in Making the ‘Case for Change’ for Healthcare Reform: A Case Study from the South Australian Transforming Health Program.
-
Appointments
Date Position Institution name 2019 - 2019 Professor of Cancer Medicine University of Adelaide 2014 - 2017 Clinical Ambassador SA Health 2011 - 2015 Service Director SA Cancer Service SA Health 2010 - 2011 Regional Clinical Director Adelaide Health Service Cancer Services 2009 - 2013 Chair South Australian Cancer Clinical Network, SA Health 2007 - 2010 Clinical Director Royal Adelaide Hospital 2007 - 2009 Chair MBBS Curriculum Committee (Operations) University of Adelaide 2007 - 2009 Deputy Chair South Australian Cancer Clinical Network 2006 - 2008 Chair MBBS Curriculum Committee University of Adelaide 2006 - 2007 Interim Clinical Director Royal Adelaide Hospital 2005 - 2007 Associate Professor in Oncological Medicine The University of Adelaide 2001 - ongoing Senior Consultant Medical Oncologist Royal Adelaide Hospital 2000 - 2004 Clinical Senior Lecturer University of Adelaide 1999 - 2002 Consultant Medical Oncologist (Access appointment) Queen Elizabeth Hospital 1999 - 2001 Associate Specialist Queen Elizabeth Hospital 1996 - 2000 Consultant Medical Oncologist Royal Adelaide Hospital 1996 - 1999 Clinical Lecturer University of Adelaide 1996 - 1997 Anti-Cancer Foundation Research Associate Queen Elizabeth Hospital 1995 - 1998 Gastroenterology Research Fellow Queen Elizabeth Hospital 1992 - 1994 Medical Oncology/Haematology Registrar Queen Elizabeth Hospital 1989 - 1992 Basic Physician Trainee Queen Elizabeth Hospital 1988 - 1988 Senior House Officer Royal Cornwall Hospital 1987 - 1988 Medical Officer/Watch Officer Britain Australia Bicentennial Schooner Trust 1986 - 1987 Medical and Surgical House Officer Royal Cornwall Hospital -
Awards and Achievements
Date Type Title Institution Name Country Amount 2014 Award MASCC Distinguished Service Award Multinational Association of Supportive Care in Cancer - - 2013 Honour Public Service Medal Queen's Birthday Honour Australia - 2009 Fellowship Woman of Achievement Award Royal College of Physicians (London) United Kingdom - 1998 Award Clinical Research Prize Queen Elizabeth Hospital Research Day Australia - 1993 Award Clinical Research Prize Queen Elizabeth Hospital Research Day Australia - 1993 Award Best Physician Trainee Queen Elizabeth Hospital Australia - -
Education
Date Institution name Country Title 2016 Birkbeck College UK Masters of Science (MSc) Medical Leadership 1999 University of Adelaide Australia Doctor of Medicine 1985 University of London UK Bachelor of Medicine and Bachelor of Surgery (MBBS)
-
Journals
-
Books
Year Citation 2013 Sonis, S., & Keefe, D. (Eds.) (2013). Pathobiology of cancer regimen-related toxicities. United States: Springer.
DOI Scopus52013 Sonis, S., & Keefe, D. (Eds.) (2013). Pathobiology of cancer regimen-related toxicities. United States: Springer.
DOI Scopus52013 Al-Dasooqi, N., Keefe, D. M., & Sonis, S. T. (2013). Mucositis.
DOI2013 Al-Dasooqi, N., Keefe, D. M., & Sonis, S. T. (2013). Mucositis.
DOI2013 Sonis, S. T., & Keefe, D. M. (2013). Preface.
DOI Scopus12013 Sonis, S. T., & Keefe, D. M. (2013). Preface.
DOI Scopus12013 Sonis, S. T., & Keefe, D. M. (2013). Conclusion.
DOI2013 Sonis, S. T., & Keefe, D. M. (2013). Conclusion.
DOI -
Book Chapters
-
Conference Papers
Year Citation 2022 Milch, V., Anderson, K., Farrugia, T., Boltong, A., & Keefe, D. (2022). Early design and feasibility assessment of a potential Lung Cancer Screening Program in Australia. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 85). WILEY. 2022 McNeill, S., Hanson, S., Elston, J., Boltong, A., & Keefe, D. (2022). Embedding equity in the Australian Cancer Plan: Engaging priority populations to improve equitable outcomes for all Australians. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 101). WILEY. 2022 Moroney, D., Lucas, K., Nehill, C., Williams, D., Mor, S., Keefe, D., & Boltong, A. (2022). A communication skills module for non-Indigenous health care professionals supporting Aboriginal and Torres Strait Islander people with cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 109). WILEY. 2022 Chaji, D., Austen, M., Cox, R., Der Vartanian, C., Boltong, A., & Keefe, D. (2022). The Australian Cancer Plan: A decision tree approach for assessment against International Standards of National Cancer Control Planning. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 100). WILEY. 2022 Keefe, D., Cox, R., Vartanian, C. D., Lambert, A., & Boltong, A. (2022). Shaping the future of cancer control - The Australian cancer plan. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 84). WILEY. 2021 Biondi, C., Milch, V., Nguyen, V., Ryan, R., Roder, D., Woods, A., . . . Keefe, D. M. K. (2021). The COVID-19 pandemic led to a reduction in cancer services in Australia.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS12021 Biondi, C., Milch, V., Nguyen, V., Ryan, R., Roder, D., Woods, A., . . . Keefe, D. (2021). Understanding the impact of the pandemic on cancer services in Australia. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 35). WILEY. 2020 Biondi, C., Nguyen, V., Milch, V., Roder, D., Woods, A., Anderiesz, C., & Keefe, D. (2020). Measuring the impact of COVID-19 on cancer services using the Medicare Benefits Schedule (MBS). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 91-92). WILEY. 2019 Bowen, J. M., Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Finnie, J. W., . . . Keefe, D. (2019). Budesonide and colesevelam reduce neratinib-induced diarrhea in a rat model. In CANCER RESEARCH Vol. 79 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI2018 Korver, S. K., Bowen, J. M., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R., . . . Coller, J. K. (2018). Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 58-59). WILEY. 2015 Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2015). Investigation of lapatinib-induced diarrhea in a tumour-bearing rat model. In Supportive Care in Cancer Vol. 23 (pp. S387). Copenhagen, Denmark: Springer Verlag (Germany).
DOI2015 Vanhoecke, B., Mayo, B., Wignall, A., Ziegler, V., Stringer, A., Bateman, E., . . . Keefe, D. (2015). Irinotecan induces DNA damage in the oral cavitiy of the Dark Agouti rats without visual signs of lesions. In Supportive Care in Cancer Vol. 23 (pp. S115). Copenhagen, Denmark: Springer Verlag (Germany).
DOI2015 Mayo, B., Stringer, A., Lucchesi, C., Bowen, J., Bateman, E., Wignall, A., . . . Keefe, D. (2015). Microbial alterations and toll-like receptor expression play a role in the improvement of irinotecan-induced mucositis after treatment with the new selective GLP-2 receptor agonist, Elsiglutide. In Supportive Care in Cancer Vol. 23 (pp. S111). Copenhagen, Denmark: Springer Verlag (Germany).
DOI2015 Ruhlmann, C. H., Christensen, T. B., Dohn, L. H., Paludan, M., Ronnengart, E., Hilpert, F., . . . Herrstedt, J. (2015). Fosaprepitant for the prevention of nausea and emesis during five weeks of chemo-radiotherapy: A multinational randomised, placebo-controlled, double-blind trial - the GAND-emesis study. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S727). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI2014 MASCC 2014 (2014). In Supportive Care in Cancer Vol. 22 (pp. 1-238). Springer Science and Business Media LLC.
DOI2013 Al-Azri, A. S., Logan, R., Gibson, R., Keefe, D., stringer, A., & Bowen, J. (2013). The role of matrix metalloproteinases and tissue inhibitors of metalloproteinase in irinotecan induced-chemotherapy. In Supportive Care in Cancer. Berlin Genrmany: Springer Verlag (Germany). 2013 Abstracts of the MASCC/ISOO (Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology) International Symposium on Supportive Care in Cancer. June 27-29, 2013. Berlin, Germany. (2013). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 21 Suppl 1 (pp. S2-301). Germany: Springer Science and Business Media LLC.
DOI Europe PMC22012 Abstracts of the 2012 International MASCC/ISOO (Multiple Association of Supportive Care in Cancer/International Society for Oral Oncology) Symposium. New York City, New York, USA. June 28-30, 2012. (2012). In Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Vol. 20 Suppl 1 (pp. 1-283). Germany: Springer Science and Business Media LLC.
DOI Europe PMC12012 Peterson, D., Keefe, D., & Sonis, S. (2012). New frontiers in mucositis. In R. Govindan (Ed.), American Society of Clinical Oncology 2012 Educational Book (pp. 545-551). Chicago, Illinois: American Society of Clinical Oncology.
DOI Europe PMC62011 Gibson, R., Mahmud, F., Bowen, J., Yeoh, A., Logan, R., & Keefe, D. (2011). Inhibition of NFkB ameliorates long term radiation-induced mucositis. In Proceedings of the 38th COSA Annual Scientific Meeting 2011 Vol. 7 (pp. 110-111). United Kingdom: Blackwell Publishing Ltd..
DOI2011 Keefe, D., & Bateman, E. (2011). Supportive care in cancer: developments in treatment and symptom management. In 49th Annual Meeting of Japanese Society of Clinical Oncology (pp. 0 pages). Nagoya Conference Centre, Japan: Japanese Society of Clinical Oncology. 2011 Al-Dasooqi, N., Mayo, B., Bowen, J., Stringer, A., Gibson, R., & Keefe, D. (2011). Pilot study of biomarkers of chemotherapy-induced Gastrointestinal Toxicity. In Proceedings of the COSA Annual Scientific Meeting Vol. 7 (pp. 1). United Kingdom: Blackwell Publishing Ltd..
DOI2011 Stringer, A., Gibson, R., Yeoh, A., Bowen, J., & Keefe, D. (2011). Chemotherapy-induced diarrhoea is associated with a modified intestinal microbiome and intestinal inflammation. In Abstracts of the 2011 International MASCC/ISOO Symposium Vol. 19 (pp. 153). 175 Fifth Ave New York NY 10010: Springer-Verlag.
DOI2011 Mayo, B., Bowen, J., Stringer, A., Bateman, E., Plews, E., Darby, J., . . . Keefe, D. (2011). The effect of ErbB inhibition on chemotherapy-induced intestinal damage. In Abstracts of the 2011 International MASCC/ISOO Symposium Vol. 19 (pp. 0 pages). 175 Fifth Ave New York NY 10010: Springer-Verlag.
DOI2011 Elting, L., Lei, X., Nguyen, H., Keefe, D., & Sonis, S. (2011). Risk of patient-reported oral mucositis during chemotherapy for colorectal cancer (CRC): do multiple cycles multiply risk?. In Abstracts of the 2011 International MASCC/ISOO Symposium Vol. 19 (pp. 0 pages). 175 Fifth Ave New York NY 10010: Springer-Verlag.
DOI2010 Al-Dasooqi, N., Bowen, J., Gibson, R., Logan, R., Stringer, A., & Keefe, D. (2010). Irinotecan-induced mucositis encompasses changes in intestinal and colonic cell kinetics and this is associated with altered extracellular matrix component expression. In Abstracts of the 2010 International MASCC/ISOO Symposium Vol. 25 (pp. 0 pages). Vancouver, Canada: Springer-Verlag.
DOI2010 Al-Dasooqi, N., Gibson, R., Bowen, J., Logan, R., Stringer, A., & Keefe, D. (2010). Matrix metalloproteinases play a pivotal role in the development of alimentary tract mucositis. In Sydney Cancer Conference (pp. 0 pages). The University of Sydney, NSW, Australia. 2010 Ruhlmann, C. H., Iversen, T. Z., Okera, M., Muhic, A., Hjelmtvedt, A., Feyer, P., . . . Herrstedt, J. (2010). IDENTIFICATION AND RANKING OF SIDE-EFFECTS IN PATIENTS RECEIVING RADIOTHERAPY AND CONCOMITANT WEEKLY CISPLATIN. A MULTINATIONAL COLLABORATIVE SURVEY. In ANNALS OF ONCOLOGY Vol. 21 (pp. 382). Milan, ITALY: OXFORD UNIV PRESS. 2010 Keefe, D. M. K. (2010). GASTROINTESTINAL TOXICITY. In ANNALS OF ONCOLOGY Vol. 21 (pp. 34). Milan, ITALY: OXFORD UNIV PRESS. 2009 Stringer, A., Gibson, R., Yeoh, A., Bowen, J., Logan, R., & Keefe, D. (2009). CHEMOTHERAPY-INDUCED DIARRHOEA IS ASSOCIATED WITH A MODIFIED MICROBIOME IN GI CANCER PATIENTS. In ANNALS OF ONCOLOGY Vol. 20 (pp. 73). Barcelona, SPAIN: OXFORD UNIV PRESS. 2008 Keefe, D. M., Elting, L. S., Sonis, S. T., Garden, A., Spijkervet, F., Barasch, A., . . . Harari, P. (2008). Treatment for head and neck cancer and for lung cancer causes significant diarrhea. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 72 (pp. S487). Boston, MA: ELSEVIER SCIENCE INC.
DOI2008 Sonis, S. T., Jacquin, P., Randolph-Jackson, P., Harari, P., Grunberg, S., Liao, Z., . . . Keefe, D. (2008). Prevalence of mouth and throat soreness (MTS) in patients undergoing lung cancer treatment, with adverse impact on functional and quality of life outcomes. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 72 (pp. S680). Boston, MA: ELSEVIER SCIENCE INC.
DOI2007 Price, T. J., Morelli, L., Howarth, G. S., Webster, J., Zacharakis, B., Brooker, C., . . . Butler, R. N. (2007). Residual damage to the small intestine induced by chemotherapy can be detected and monitored using the non-invasive <SUP>13</SUP>C Sucrose Breath Test (SBT). In EJC SUPPLEMENTS Vol. 5 (pp. 152). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2007 Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Serum levels of nuclear factor-κB and tumour necrosis factor following irinotecan administration in the Dark Agouti rat. In ORAL ONCOLOGY (pp. 211). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV. 2007 Logan, R., Gibson, R., Stringer, A., Bowen, J., Sonis, S., & Keefe, D. (2007). Nuclear factor-KB and cyclooxygenase-2 expression in the oral mucosa following cancer chemotherapy. In ORAL ONCOLOGY (pp. 171). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV. 2007 Aprile, G., Ramoni, M., Keefe, D., & Sonis, S. (2007). Acute toxicities in colorectal cancer (CRC) patients undergoing chemotherapy (CT): Clustering and cycle-to-cycle prediction by means of Bayesian analysis. In ANNALS OF ONCOLOGY Vol. 18 (pp. 12). Palermo, ITALY: ELSEVIER. 2007 Joshi, R., O'Neill, S., & Keefe, D. (2007). A prospective audit of inpatient medical oncology consultation patterns in a tertiary teaching hospital in South Australia. In ANNALS OF ONCOLOGY Vol. 18 (pp. 196-197). Lugano, SWITZERLAND: OXFORD UNIV PRESS. 2007 Keefe, D. M. K. (2007). Oral mucositis: pathobiology and treatment guidelines. In ORAL ONCOLOGY (pp. 50). Amsterdam, NETHERLANDS: ELSEVIER SCIENCE BV. 2007 Garden, A. S., Tishler, R. B., Araschl, A., Brennan, M. T., Harari, P. M., Kudrimoti, M. R., . . . Keefe, D. (2007). Adverse impact of mucositis on health related quality of life outcomes and resource use in head and neck cancer patients receiving radiation. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 69 (pp. S179-S180). Los Angeles, CA: ELSEVIER SCIENCE INC.
DOI WoS12007 Elting, L. S., Calais, G., Selva, N., Brachman, D., Kudrimoti, M., Spijkervet, F., . . . Sonis, S. T. (2007). Patient-reported burden of mucosal injury (MUI): Comparison of clinician-rated MUI and patient-reported outcomes. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
WoS12007 Aprile, G., Ramoni, M., Keefe, D., & Sonis, S. (2007). Network analyses to define chemotherapy toxicity clusters in patients with colorectal cancer (CRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
WoS32007 Keefe, D. M., Garden, A., Barasch, A., Tischler, R., Brennan, M., Trotti, A., . . . Sonis, S. (2007). Oral mucositis is associated with increased resource use among patients receiving treatment for cancers of the head and neck. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. 2006 Vera-Llonch, M., Sonis, S. T., Keefe, D., Elting, L., Edelsberg, J., Isitt, J., . . . Oster, G. (2006). Identifying potential mucositis-related infection resource use in solid tumor cancer patients. In ANNALS OF ONCOLOGY Vol. 17 (pp. 286). Istanbul, TURKEY: ELSEVIER. 2006 Elting, L. S., Keefe, D., Sonis, S. T., Morales, M., Molassiotis, A., Isitt, J., . . . Vera-Llonch, M. (2006). Burden of illness and economic impact of mucosal injury (MUI) in solid tumor-a multinational prospective observational study design. In ANNALS OF ONCOLOGY Vol. 17 (pp. 297). Istanbul, TURKEY: ELSEVIER. 2005 Pittman, K. B., Olver, I. N., Karapetis, C. S., Kotasek, D., Price, T. J., Patterson, W. K., . . . Greer, D. (2005). Mulicenter phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 764S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS1 -
Conference Items
Year Citation 2021 Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Diala, I., Lalani, A. S., & Bowen, J. M. (2021). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.. Poster session presented at the meeting of CANCER RESEARCH. Philadelphia, PA: AMER ASSOC CANCER RESEARCH. 2019 Coller, J. K., Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., . . . Bowen, J. M. (2019). Predictors of severe gastrointestinal toxicity risk in patients treated with 5-fluorouracil-based chemotherapy: A validation study. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Ruhlmann, C. H., Christensen, T. B., Dohn, L. H., Paludan, M., Roennengart, E., Hilpert, F., . . . Herrstedt, J. (2017). Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS. 2017 Bowen, J., Ball, I., Thompson, S., Irvine, T., Chiam, K., Hussey, D., . . . Keefe, D. (2017). Identification of Inflammatory Markers of Chemoradiotherapy-Induced Gastrointestinal Toxicity in Oesophageal Cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Logan, R. M., Karapetis, C. S., Keefe, D. M., . . . Coller, J. K. (2017). The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Korver, S. K., Ball, I. A., Gibson, R. J., Tuke, J., Logan, R. M., Richards, A., . . . Coller, J. K. (2017). Interleukin-1 Beta (<i>IL1B</i>) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2017 Bautista, M. J., Ahmedzai, S. H., Bouzid, K., Gibson, R., Gumara, Y., Hassan, A. A. I., . . . Wang, J. J. (2017). A framework for education and advocacy for optimal cancer pain management in resource-limited settings. Poster session presented at the meeting of Annals of Oncology. Singapore, SINGAPORE: OXFORD UNIV PRESS.
DOI2016 Abstracts of the MASCC/ISOO 2016 Annual Meeting. (2016). Poster session presented at the meeting of Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Germany: Springer Science and Business Media LLC.
DOI2015 Stansborough, R. L., Bateman, E., Al-Dasooqi, N., Keefe, D., & Gibson, R. (2015). Microvascular injury and associated mediator changes occur during acute radiotherapy-induced gut toxicity. Poster session presented at the meeting of Supportive Care in Cancer. Copenhagen, Denmark: Springer Verlag (Germany). 2015 Lacouture, M. E., Keefe, D., Sonis, S. T., Giri, N., Wang, T., Reisman, A., . . . Jatoi, A. (2015). Impact of Prophylactic Doxycycline (Doxy) on Maintaining Planned Dosing of Dacomitinib (D) an Irreversible panHER Inhibitor. Poster session presented at the meeting of JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. 2014 Mayo, B., Bateman, E., Stringer, A., Plews, E., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). The new selective GLP-2 receptor agonist, Elsiglutide, improved irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany). 2014 Mayo, B., Stringer, A., Bateman, E., Bowen, J., Pietra, C., Cantoreggi, S., & Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective GLP-2 receptor agonist, Elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Supportive Care in Cancer. Miami, USA: Springer Verlag (Germany). 2014 Keefe, D. (2014). MUCOSITIS AND ITS LINKS TO OTHER TOXICITIES IN LUNG CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2014 Mayo, B., Bateman, E., Stringer, A., Plews, E., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI2014 Mayo, B., Stringer, A., Bateman, E., Bowen, J., Wignall, A., Wozniak, B., . . . Keefe, D. (2014). Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositis. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI2014 Bessen, T., Chen, G., Street, J., Eliott, J., Karnon, J., Keefe, D., & Ratcliffe, J. (2014). What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI2014 Fan, C., Georgiou, K. R., McKinnon, R. A., Keefe, D. M., Howe, P. R., & Xian, C. J. (2014). ADVERSE EFFECTS OF COMBINATION BREAST CANCER CHEMOTHERAPY ON BONE AND BONE MARROW. Poster session presented at the meeting of OSTEOPOROSIS INTERNATIONAL. Taipei, TAIWAN: SPRINGER LONDON LTD. 2014 Benge, S., Perez, D., Sharples, K., Broom, R., Jeffery, M., Proctor, J., . . . Findlay, M. (2014). ASSESSING THE EFFICACY OF ICE-CREAM-FORMULATED IRON-SATURATED LACTOFERRIN AND ANHYDROUS MILK FAT IN PREVENTING CHEMOTHERAPY INDUCED DIARRHOEA - THE RECHARGE STUDY, A RANDOMISED PHASE IIB TRIAL. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2013 Keefe, D., Kim, H. -K., Chan, A., Hsieh, R. K., Yu, S. Y., Hernandez, A. B., & Burke, T. (2013). CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN THE ASIA-PACIFIC (AP) REGION - THE AUSTRALIAN PERSPECTIVE FROM THE PAN-AUSTRALASIAN CHEMOTHERAPY INDUCED EMESIS STUDY (PRACTICE). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2013 Mayo, B., Bateman, E., Stringer, A., Plews, E., Pishas, K., Pietra, C., . . . Keefe, D. (2013). The effect of the new selective GLP-2 agonist, elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide Convention Centre, Adelaide, South Australia: Wiley Publishing Asia.
DOI2013 Lacouture, M., Grunberg, S., Keefe, D., Sonis, S., Ely, J., Gernhardt, D., . . . Jatoi, A. (2013). Impact of doxycycline (doxy) prophylaxis on dermatologic toxicity from dacomitinib (D) for NSCLC, by CTCAE and patient (pt)-reported outcomes (PRO) measures in a placebo-controlled trial. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. 2013 Radzuan, M., Bateman, E., Bowen, J., Keefe, D., & Stringer, A. (2013). Intestinal Lactobacillus spp. increase following radiotherapy in rats: an unusual finding. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany). 2013 Bateman, E., Wilson, C., Keefe, C., Bowen, J., Wignall, A., Plews, E., & Keefe, D. (2013). Fractionated radiotherapy in a rat model causes dose-dependent changes in collagen deposition, and expression of transforming growth factor β1, Smad3 and smooth muscle actin α1. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
DOI2013 Mayo, B., Bateman, E., Stringer, A., Plews, E., Pishas, K., Pietra, C., . . . Keefe, D. (2013). The effect of the new selective GLP-2 agonist, Elsiglutide, on irinotecan-induced diarrhoea and mucositis in the rat.. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
DOI2013 Wan Mohamad Zain, W., Bowen, J., Bateman, E., & Keefe, D. (2013). Development of a walker 256-TC tumour-bearing rat model to study lapatinib-induced mucosal injury. Poster session presented at the meeting of Supportive Care in Cancer. Berlin, Germany: Springer Verlag (Germany).
DOI2012 Keefe, D. (2012). GASTROINTESTINAL TOXICITY IN ONCOLOGY: EVOLUTIONARY SCIENCE. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Vienna, AUSTRIA: OXFORD UNIV PRESS. 2011 Bateman, E., Bowen, J., Mayo, B., Plews, E., Darby, J., Stringer, A., . . . Keefe, D. (2011). Further characterisation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-induced diarrhoea. Poster session presented at the meeting of Abstracts of the 2011 International MASCC/ISOO Symposium, as published in Supportive Care in Cancer. Athens: Springer-Verlag.
DOI2009 Stringer, A. M., Gibson, R. J., Bowen, J. M., Logan, R. M., Al-Dasooqi, N., & Keefe, D. M. K. (2009). Chemotherapy-induced diarrhoea is associated with a modified microbiome in cancer patients. Poster session presented at the meeting of Abstracts of the Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, as published in Journal of Gastroenterology and Hepatology. Sydney, N.S.W.: Wiley-Blackwell.
DOI2000 Olver, I., Vadas, M., Lopez, A., Keefe, D., Taylor, A., Brown, M., & To, L. (2000). A phase 1 study of the GM-CSF antagonist E21R. Poster session presented at the meeting of Proceedings of ASCO - Volume 19 2000. USA: American Society of Clinical Oncology.
DOI2000 Gibson, R., Keefe, D., Clarke, J., Regester, G., Edwards, B., Thompson, F., . . . Cummins, A. (2000). Interleukin-11 (IL-11) reduces, but not completely ameliorates, intestinal mucositis following chemotherapy in the rat with breast cancer. Poster session presented at the meeting of Abstracts for Australian Gastroenterology Week 2000. Victoria, Australia: Blackwell Science Asia. -
Theses
Year Citation 2013 Al-Azri, A. S. (2013). The role of matrix metalloproteinases and their inhibitors in irinotecan-induced oral mucositis: an animal model. (PhD Thesis, The University of Adelaide). 2008 Logan, R. M. (2008). Alimentary tract mucositis: NF-kB and pro-inflammatory cytokines in the tissues and serum following chemotherapy. (PhD Thesis).
Date | Project/ No. | Investigators | Funding Body | Amount |
---|---|---|---|---|
2014 |
Role of Inflammatory Signalling on Burden of Illness in Mucositis. |
Keefe D, Gibson R, Bowen J & Coller J | TRIAD | $12,000 |
2014 |
Prevention of dacomitinib induced diarrhoea by targeting chloride secretion. |
Bowen J & Keefe D. | Pfizer | $80,000 |
2014 |
South Australian Health and Medical Research Institute – SAHMRI. Innovative Cancer Imaging and Therapeutics Facility. |
C Mulligan, T Hughes, A Zannettino, S Gronthos, D White, D Keefe, T Mondo, D Roder, W Tilley, T Price and P MacKenzie | ACRF | $1.8M |
2014 |
Cancer Data and Aboriginal Disparities – CANDAD. Development and testing of an integrated cancer monitoring and surveillance system for Aboriginal People in South Australia. |
A Brown, D, Rodda, M Cargo, D Keefe, M Eckert, G Farshid | NHMRC | $1,034,270 |
2013 |
Studies on the effect of Enteragam on gastrointestinal mucositis. |
D Keefe & E Bateman. | Entera Health | $100,000 |
2013 |
Protecting tissues from chemotherapy. |
Callen D, Keefe D, Neilsen P, Smid S | NHMRC | $565,847 |
2012 |
Study into effect of Elsiglutide on gastrointestinal mucositis |
Keefe, Bowen, Stringer and Bateman | Helsinn Healthcare | $130,000 |
2012 |
Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours |
D Watson, D Keefe, D Hussey and J Bowen | NHMRC | $481,175 |
2012 |
A Nanostructured Drug Delivery Approach for Improved Colorectal Cancer Therapy. |
C Prestidge, B Boyd & D Keefe | NHMRC | $541,010 |
2012 |
Cyclotherapy: a promising new approach to prevent the side effects of chemotherapy. |
P M Neilsen & D M K Keefe | RAH Research Committee | $35,000 |
2010 |
Improving colorectal cancer therapy using a novel nanotechnology-based delivery system. |
C Prestidge, B Boyd, MP Brown, D Keefe, A Davey | Cancer Council SA | $110,000 |
2010 |
Oral Mucositis Risk and Multicyle Chemotherapy: do multiple cycles multiply risk |
L Elting, S Sonis and D Keefe | NIDCR | $150,000 |
2010 |
CCRE in Oral Health, University of Adelaide |
M Bartold, J Spencer, G Townsend, K Roberts-Thompson & D Keefe | NHMRC | $2.5m |
2009 |
Studies of Nutritional Supplements as prevention/treatment for gastrointestinal toxicity of chemotherapy |
Nestec | $250,000 | |
2008 |
Investigation of probiotic VSL #3 in DA rat model of mucosal injury. |
VSL Pharma | $100,000 | |
2009 |
Faecal microflora and circulating pro-inflammatory cytokines: key elements to chemotherapy- induced diarrhoea. |
R Gibson, J Bowen, A Stringer, R Logan and D Keefe. | Cancer Australia | $75, 000 |
2008 |
Characterisation of Tyrosine Kinase inhibitor-induced gastrointestinal toxicity |
D Keefe & F Boyle | GSK | $620, 000 |
2008 |
Distiller image analysis software and server |
Tilley, Owens, Norman, Findlay, Keefe | NHMRC equipment grant | $52,000 |
2007 |
Automated image analysis system for the high throughput immuno-histochemical analysis of clinical and experimental samples. |
Tilley, Owens, Norman, Findlay, Keefe & al | NHMRC equipment grant | $100,695.83 |
2007 |
Triad Mucositis Burden of Illness Study: Chronic mucosal injury study |
Elting, Keefe & Sonis | Amgen Inc. | USD $900,000 |
2006 |
Triad Mucositis Burden of Illness Study: Acute mucosal injury cohort expansion |
Elting, Keefe & Sonis | Amgen Inc. | USD $609,000 |
2006 |
Chemotherapy-induced diarrhoea: Characterisation of mechanism |
D Keefe | The Cancer Council South Australia | $70,500 |
2006 |
Oral mucositis: clinical presentation, histological features and pro-inflammatory cytokine expression |
R Logan, R Gibson, D Keefe & S Sonis | Australian Dental Research Foundation Inc. (ADRF) | $3000 |
2005 |
Assessment of an oral supplement in adult cancer patients with mucositis. |
R Butler, P Bardy, T Price, J Davidson, D Keefe & J Webster | Biotechnology Innovation Fund (BIF) Grant | $490,000 |
2005 |
Triad Mucositis Burden of Illness Study |
Elting, Keefe & Sonis | Amgen Inc. | USD $3,600,000 |
2005 |
Triad Mucositis Burden of Illness Study: project scoping study |
Elting, Keefe & Sonis | Amgen Inc. | US$ 100,000 |
2005 |
Investigation of Probiotic effect on mucositis in the DA rat |
D Keefe: Joint venture with Professor Claudio de Simone | VSL | $30,000 |
2004 |
Studies to investigate CG53135 for mucositis treatment in the DA rat mammary adenocarcinoma (DAMA) model |
D Keefe | Curagen | USD$300, 000 |
2004 |
Oral Mucositis in humans |
D Keefe | RAH Research Fund | $15,000 |
2003 |
Studies of KGF/CPT-11 in the DAMA mucositis model |
D Keefe | RAHCC Internal funding | $60,000 |
2001 |
Keratinocyte growth factor research in mucositis |
D Keefe | mgen Inc. | $50,000 |
2001 |
Further studies in mucositis in rats and humans undergoing cytotoxic chemotherapy f or cancer |
D Keefe | Anti-cancer Foundation | $54,425 |
2000 |
Development of the DAMA model |
D Keefe | RAHCC Internal Funding | $60,000 |
1999 |
Mucositis in the rat with breast cancer. |
D Keefe | The Queen Elizabeth Hospital (TQEH) Research Foundation | $10,000 |
1999 |
Investigation and prevention of intestinal mucositis after chemotherapy in the rat with breast cancer |
D Keefe | Anti Cancer Foundation | $52,000 |
1997 |
Mucositis research |
D Keefe & A Cummins | B3 funding University of Adelaide | $5,000 |
1997 |
Mucositis Research |
D Keefe & A Cummins | TQEH Research Foundation | $5,400 |
1995 |
The effect of cancer and chemotherapy on nutrition, and on inducing malabsorption by an immunological mediated enteropathy |
D Keefe & A Cummins. | Anti-Cancer Foundation | $52,000 |
Teaching and Training Innovations and Materials Developed
Date | Course Details |
---|---|
2011-2017 |
Chair, Board of Examiners Years 4 and 5, MBBS Curriculum, University of Adelaide |
2006 |
Initiated and chaired the inaugural meeting of the Chairs of Australian Medical School Curriculum Committees |
2005 |
Developed and conducted the inaugural "Exam Setting Workshop" for the Year 5 final barrier exam for the new medical school curriculum. |
2004-2005 |
Inaugural Co-ordinating Examiner for the Year 5 final barrier exam |
2003-2005 |
Chair of Common Program subcommittee of the MBBS Curriculum Committee. Developed common program for new medical school curriculum |
Curriculum Development
Date | Course Details |
---|---|
2004-2005 |
Member Assessment Committee, MBBS Curriculum |
2004-2005 |
Member of Year 6 Committee |
2003-2005 |
Member of Year 4/5 Committee |
2002-2005 |
Member MBBS Curriculum Committee during development of new curriculum |
1999 |
Member of Oncology Concept Mapping Group for development of Curriculum 2000 |
Curriculum Review
Date | Course Details |
---|---|
2006 |
Submission to the University of Adelaide review of the MBBS program on behalf of the curriculum committee |
2006 |
Member of working group developing submission to the Australian Medical Council regarding accreditation of the University of Adelaide MBBS program. Accreditation achieved until 2011. |
2005 |
Royal Adelaide Hospital Physicians’ Committee Curriculum Workshop. Developed and facilitated a review of medical student selection and assessment, as well as course structure, and generated a report for the University of Adelaide |
Post Graduate Medical Training
Date | Course Details |
---|---|
2006-2014 |
RACP State representative for assessment of overseas training in Medical Oncology |
2006/2011 |
Re-accredited supervisor for Medical Oncology Trainees of the Royal Australasian College of Physicians |
1996-2007 |
Long-case FRACP trial examiner, Basic Physician Trainees, RAH |
1999-2006 |
Intern Term Supervisor, Medical Oncology |
Communication Skills Training
Date | Course Title |
---|---|
2006 |
NBCC Train the Trainers workshop Training future facilitators for communications workshops in cancer |
2006 |
Medical Oncology Group of Australia, Trainee Communications Workshop Training Medical Oncology and Palliative Care Advanced Trainees in communication skills, and mentoring newly trained facilitators |
2005 |
American Society for Clinical Oncology/Clinical Oncological Society of Australia (ASCO/COSA) communication skills workshop: Facilitator |
Assessment
Date | Course Title |
---|---|
2008-2017 |
Chair, MBBS, Year 4/5 Board of Examiners |
2007 |
Member of Academic Progress Review Committee Faculty of Health Sciences |
2002-2006 |
OSCE Examiner for Medical School |
2000-2010 |
Local Examiner for Royal Australasian College of Physicians |
-
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2014 - 2018 Co-Supervisor Intestinal Microvascular Changes and Matrix Metalloproteinases in Radiotherapy-Induced Gastrointestinal Toxicity Doctor of Philosophy Doctorate Full Time Romany Laura Stansborough 2011 - 2012 Co-Supervisor The Safe Administration of Rapid Rituximab Infusion: An Evidence-Based Approach Doctor of Philosophy Doctorate Full Time Miss Siew Ping Lang 2011 - 2016 Principal Supervisor In vitro and in vivo Models to assess the mechanism of Lapatinib - Induced Diarrhoea Doctor of Philosophy Doctorate Full Time Mrs Wan Nor I'zzah Wan Mohamad Zain 2009 - 2013 Co-Supervisor The Role of Matrix Metalloproteinases and their Inhibitors in Irinotecan-Induced Oral Mucositis: An Animal Model Doctor of Clinical Dentistry Doctorate Full Time APrf Abdul Rahman Al 'Azri 2009 - 2014 Co-Supervisor Optimising follow-up for women after primary treatment for early breast cancer Doctor of Philosophy Doctorate Part Time Dr Taryn Bessen 2009 - 2013 Co-Supervisor Assessment of oral mucositis, oral health outcomes, and implementation of a standardized oral health care protocol for a pediatric inpatient population receiving cancer treatment. Doctor of Clinical Dentistry Doctorate Full Time Dr Akram Fareed Qutob 2008 - 2008 Other Exploring the Collective Utility of Population-Based & Clinical Cancer Registries in Assessing Epidemiological, Treatment & Outcome Characteristics of Cancer in South Australia Doctor of Medicine Doctorate Full Time Dr Colin Glen Luke 2008 - 2012 Co-Supervisor Chemotherapy-Induced Mucositis: The Role of Matrix Metalloproteinases and the Extracellular Matrix Doctor of Philosophy Doctorate Full Time Miss Noor Al-Dasooqi 2006 - 2009 Principal Supervisor Chemotherapy-Induced Mucositis: The Role of Gastrointestinal Microflora and Mucins in the Luminal Environment Doctor of Philosophy Doctorate Full Time Dr Andrea Marie Stringer 2004 - 2008 Principal Supervisor Alimentary Tract Mucositis: NF-KB and Pro-Inflammatory Cytokines in the Tissues and Serum Following Chemotherapy Doctor of Philosophy Doctorate Part Time Prof Richard Logan 2002 - 2004 Principal Supervisor Chemotherapy-induced mucositis: Mechanisms of damage, time course of events and possible preventative strategies. Doctor of Philosophy Doctorate Full Time Prof Rachel Gibson 2002 - 2006 Co-Supervisor Chemotherapy-Induced Intestinal Mucositis: The Role of Apoptosis Regulators Doctor of Philosophy Doctorate Full Time Prof Joanne Bowen
-
Board Memberships
Date Role Board name Institution name Country 2014 - ongoing Board Member Breast Cancer Network Australia - Australia -
Committee Memberships
Date Role Committee Institution Country 2014 - ongoing Member Inaugural Palliative Oncology Meeting ASCO United States 2014 - ongoing Member Annual Scientific Meeting ESMO Spain 2014 - ongoing Member Annual Scientific Meeting MASCC United States 2013 - ongoing Member Annual Scientific Meeting MASCC Germany 2013 - ongoing Member SA Comprehensive Cancer Consortium Steering Committee SAHMRI Australia 2013 - 2014 President The Multinational Association for Supportive Care in Cancer - - 2012 - ongoing Member Beat Cancer Project Research Leadership Group SAHMRI Australia 2012 - ongoing Member Clinical Research and Drug and Device Development Pillar Committee SAHMRI Australia 2012 - ongoing Member Annual Scientific Meeting ESMO Austria 2011 - ongoing Member Annual Scientific Meeting MASCC Greece 2010 - ongoing Member Annual Scientific Meeting European Society for Medical Oncology Italy 2010 - ongoing Member Annual Scientific Meeting Multinational Association of Supportive Care in Cancer Canada 2010 - 2012 President The Multinational Association for Supportive Care in Cancer - - 2010 - ongoing Member Scientific Advisory Group SA Cancer Research Collaborative Australia 2009 - 2013 Member South Australian Clinical Senate - Australia 2009 - 2011 Member Cancer Research Advisory Committee The Cancer Council South Australia Australia 2009 - ongoing Member Annual Scientific Meeting Multinational Association of Supportive Care in Cancer Italy 2008 - 2010 Vice-President The Multinational Association of Supportive Care in Cancer) - - 2007 - 2010 Chair Optimising Cancer Care Subcommittee Cancer Clinical Network - 2006 - 2010 Chair Governance Subcommittee MASCC - 2006 - 2008 Member Communication Steering Committee National Breast Cancer Centre Australia 2006 - 2008 Member Cancer Council Helpline Advisory Panel Cancer Council South Australia Australia 2006 - ongoing Member Annual Scientific Meeting Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology Canada 2005 - ongoing Member Annual Scientific Meeting The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology Switzerland 2005 - 2006 Member Member Workforce Subcommittee Statewide Cancer Control Plan Australia 2004 - 2008 Member Board of Directors MASCC Australia 2004 - 2008 Chair Mucositis Study Group MASCC Australia 2004 - ongoing Member The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology The Multinational Association of Supportive Care in Cancer/ International Society of Ocular Oncology United States 2003 - 2011 Member Board of Directors The Cancer Council South Australia Australia 2003 - 2006 Member National Grants Steering Committee The Cancer Council Australia Australia 2003 - 2006 Member Peter Nelson Leukemia Research Fellowship Committee - - 2003 - 2006 Chair Cancer Research Advisory Committee The Cancer Council South Australia Australia 2002 - 2006 Member Education Subcommittee Medical Oncology Group of Australia Australia 1999 - 2001 Member Cancer Research Advisory Committee The Cancer Council South Australia Australia
Connect With Me
External Profiles